NeuroTronik Limited


Contact Fred McCoy
Title CEO


The NeuroTronik Neuromodulation System™, in development, is a novel medical technology approach to help physicians treat heart failure patients who come to the hospital because of their worsened symptoms.
Acute Heart Failure Syndrome (AHFS) is a leading reason for older-adult hospitalizations in every developed healthcare market around the world. AHFS represents a difficult clinical and economic challenge for patients, physicians, hospitals, and payers.

Company News

NeuroTronik Closes on a $23.1M Series B

DateApr 19, 2017
NeuroTronik Limited and NeuroTronik, Inc. today announced closing on a $23.1 million Series B Preferred Stock Financing, tranched in line with project plan milestones.